FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
Xiaoyong Fu(King University), Rachel Schiff(Baylor College of Medicine), Martin J. Shea(Baylor College of Medicine), Dolores López‐Terrada(Cleveland Clinic), Carolina Gutiérrez(Baylor College of Medicine), Carmine De Angelis(Baylor College of Medicine), C. Kent Osborne(Baylor College of Medicine), Joe W. Gray(Norwegian Cancer Society), Shixia Huang(Southwest University), Myles Brown(Harvard University), Paul T. Spellman(Oregon Health & Science University), Meghana V. Trivedi(University of Houston), Pavana Anur, Chad J. Creighton(Baylor College of Medicine), Rinath Jeselsohn(Dana-Farber Cancer Institute), Agostina Nardone(AstraZeneca (Spain)), Mothaffar F. Rimawi(Baylor College of Medicine), Catherine S. Grasso(University of California, Los Angeles), Susan G. Hilsenbeck(Baylor College of Medicine), Anna Tsimelzon(Pancreatic Cancer Action Network), Emporia Faith Hollingsworth(Baylor College of Medicine), Laura M. Heiser(Oregon Health & Science University), Resel Pereira(Baylor College of Medicine), Dean P. Edwards(Baylor College of Medicine), Fugen Li(Precision for Medicine (United States)), Nicholas Wang(Oregon Health & Science University), Obi L. Griffith(Washington University in St. Louis)
Cited by 185
Related Papers
Model-based Analysis of ChIP-Seq (MACS)
|Genome biology|2008|20k
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
|Neoplasia|2017|6.5k
UALCAN: An update to the integrated cancer data analysis platform
|Neoplasia|2022|2.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k